UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
9.84
-0.27 (-2.67%)
Apr 25, 2025, 4:00 PM EDT - Market closed
UroGen Pharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for UroGen Pharma stock have an average target of 37.21, with a low estimate of 16 and a high estimate of 55. The average target predicts an increase of 278.15% from the current stock price of 9.84.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $22 → $16 | Hold | Maintains | $22 → $16 | +62.60% | Apr 17, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +154.07% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $64 → $55 | Strong Buy | Maintains | $64 → $55 | +458.94% | Mar 11, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +154.07% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $64 | Strong Buy | Reiterates | $64 | +550.41% | Feb 25, 2025 |
Financial Forecast
Revenue This Year
125.34M
from 90.40M
Increased by 38.65%
Revenue Next Year
274.11M
from 125.34M
Increased by 118.69%
EPS This Year
-2.97
from -2.96
EPS Next Year
-0.68
from -2.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 144.4M | 411.1M | 741.7M | ||
| Avg | 125.3M | 274.1M | 436.6M | ||
| Low | 106.0M | 168.1M | 235.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 59.7% | 227.9% | 170.6% | ||
| Avg | 38.7% | 118.7% | 59.3% | ||
| Low | 17.2% | 34.1% | -14.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.80 | 2.14 | 4.24 | ||
| Avg | -2.97 | -0.68 | 1.62 | ||
| Low | -3.64 | -2.35 | -0.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.